Webinar-Recorded

Webinar-Small Molecule Orphan Drugs: Status Quo, Challenges, and Perspectives

The development of orphan drugs in the past year has continued to trend upwards in the US, the European Union, and Japan. This is due to the financial incentives offered through regulation, with orphan designation appearing to be successful at generating opportunities and positive value for drug sponsors and patients. Despite that, many rare diseases remain without effective treatments despite the rising number of approved orphan drug products. In addition, the decision to invest in the orphan drug space is more complex than simply responding to regulatory incentives. In this webinar, experts discuss the key drivers that motivate drug sponsors in developing orphan drugs. In addition, experts explore the challenges of orphan drug development and manufacturing and will discuss how the industry is leveraging strategic partnerships to help mitigate these challenges to create a viable orphan drug business model.

Learn more about:

Understand the drivers of growth in orphan drug investment and development

Learn how to navigate the complex development and manufacturing space of orphan drugs

Discuss practical considerations for supply chain when bringing an orphan drug to the clinical and market

Business Email Address*

First Name*

Last Name*

Company*

Title*

Business Phone

Country

State or Province

Buying Horizon*

Asset ID

Asset Type

Asset URL

Download Center - Date Stamp

Download Center - Visit Count

ZZ - Last SFDC Campaign ID

Unique ID

Browser

auxCountry

auxState

Why Catalent?

Catalyst + Talent

Catalent is the global leader in enabling pharma, biotech, and consumer health partners to optimize product development, launch, and full life-cycle supply for patients around the world. With broad and deep scale and expertise in development sciences, delivery technologies, and multi-modality manufacturing, Catalent is a preferred industry partner for personalized medicines, consumer health brand extensions, and blockbuster drugs. Catalent helps accelerate over 1,000 partner programs and launch over 150 new products every year. Its flexible manufacturing platforms at over 50 global sites supply over 70 billion doses of more than 7,000 products to over 1,000 customers annually. Catalent’s expert workforce exceeds 17,000, including more than 2,500 scientists and technicians. Headquartered in Somerset, New Jersey, the company generated $4 billion in revenue in its 2021 fiscal year. For more information, visit www.catalent.com.

More products. Better treatments. Reliably supplied.™